High-Flow Oxygen and Other Noninvasive Respiratory Support Therapies in Bronchiolitis: Systematic Review and Network Meta-Analyses.

Objectives: We present a systematic review on the effectiveness of noninvasive respiratory support techniques in bronchiolitis.

Data Sources: Systematic review with pairwise meta-analyses of all studies and network meta-analyses of the clinical trials.

Study Selection: Patients below 24 months old with bronchiolitis who require noninvasive respiratory support were included in randomized controlled trials (RCTs), non-RCT, and cohort studies in which high-flow nasal cannula (HFNC) was compared with conventional low-flow oxygen therapy (LFOT) and/or noninvasive ventilation (NIV).

Comparison of the accuracy of 11 intraocular lens power calculation formulas.

Purpose: To compare the accuracy of 11 intraocular lens (IOL) power calculation formulas (SRK-T, Hoffer Q, Holladay I, Haigis, Holladay II, Olsen, Barrett Universal II, Hill-RBF, Ladas Super formula, EVO and Kane).

Setting: Private university hospital (QuironSalud, Madrid, Spain).

Design: Retrospective case series.

[Descriptive statistical analysis of the treatment of status epilepticus in a referral hospital].

Introduction: Status epilepticus is defined as either recurring seizures without regaining consciousness between them or one single seizure lasting more than 30 minutes.

Aims: To perform a descriptive analysis of the most relevant data on the patients with status epilepticus who were admitted to a paediatric intensive care unit (PICU) and to review the risk factors associated to status epilepticus with a poor prognosis.

Patients And Methods: A study was conducted of the main variables of the patients with status epilepticus hospitalised in the PICU of a tertiary hospital over a period of six years.

Spontaneous clearance of HCV in HIV-hepatitis C virus coinfected liver transplant patients: prospective study.

Background: Hepatitis C virus (HCV) clearance is an independent predictive factor for long-term survival in HIV-HCV liver transplantation patients. After 46 months of antiviral therapy it is achieved in up to 80% of cases. Little is known, however, about spontaneous viral clearance.